Yahoo Finance

ORYZON to Present Preliminary Blinded Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder

MADRID, Spain and BOSTON, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop ...
Yahoo Finance

ORYZON to Present Preliminary Blinded Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder

At the 10 th European Conference on Mental Health (ECMH) Company expects to perform an interim analysis in 1Q23 MADRID, Spain and BOSTON, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN ...
Yahoo Finance

Positive Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder

Recommendation from the independent Data Monitoring Committee (DMC) to continue the PORTICO trial based on positive safety data from the initial 167 randomized patients PORTICO plans to recruit 188 ...
Mena FN

ORYZON Presents Blinded Aggregate Safety Data From Vafidemstat's Ongoing Phase Iib PORTICO Trial In Borderline Personality Disorder

MADRID, Spain and BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies ...
ascopubs.org

Nonrandomized Comparison of Primary Chemotherapy and Retroperitoneal Lymph Node Dissection for Clinical Stage IIA and IIB Nonseminomatous Germ Cell Testicular Cancer

Significance of Multifocality in Ductal Carcinoma In Situ: Outcomes of Women Treated With Breast-Conserving Therapy Patients with clinical stage (CS) IIA and IIB nonseminomatous germ cell tumor (NSGCT ...